DVT Prophylaxis for Hospitalized Adult Patients
For acutely ill hospitalized medical patients at acceptable bleeding risk, use pharmacologic prophylaxis with LMWH (enoxaparin 40 mg once daily or dalteparin 5000 IU once daily), low-dose unfractionated heparin (5000 U every 8 hours), or fondaparinux (2.5 mg once daily) throughout hospitalization. 1, 2
General Medical Patients
For hospitalized medical patients, prophylaxis selection depends on bleeding risk stratification:
- Standard risk patients: Use LMWH, low-dose UFH (twice or thrice daily), or fondaparinux continued throughout hospitalization (Grade 1B) 1
- High bleeding risk patients: Use mechanical thromboprophylaxis with graduated compression stockings and/or intermittent pneumatic compression (Grade 2C) 1
- Duration: Continue throughout hospitalization or until fully ambulatory 3, 4
Do not extend pharmacologic prophylaxis after hospital discharge for general medical patients - this is a strong recommendation as extended prophylaxis has not shown benefit and increases bleeding risk 2.
Specific Dosing for Medical Patients:
- Enoxaparin: 40 mg subcutaneous once daily 3, 1, 4
- Dalteparin: 5000 IU subcutaneous once daily 3, 1, 4
- UFH: 5000 U subcutaneous every 8 hours (every 12 hours is less effective) 3, 4, 5
- Fondaparinux: 2.5 mg subcutaneous once daily 3, 1, 4
Major Orthopedic Surgery (Hip/Knee Arthroplasty)
All patients undergoing major orthopedic surgery should receive prophylaxis with a pharmacologic agent or intermittent pneumatic compression device for a minimum of 10-14 days, with extended prophylaxis up to 35 days. 6
Timing After Surgery - Critical Detail:
Start the first dose 6-10 hours after surgery - this timing balances efficacy and bleeding risk 7, 1, 8. Evidence shows:
- Starting <6 hours postoperatively increases major bleeding without improved efficacy 8
- Starting preoperatively (within 2 hours of surgery) increases major bleeding 8
- Starting 12-24 hours postoperatively may be less effective than 6 hours 7, 8
Orthopedic Surgery Dosing:
For hip or knee replacement:
- Enoxaparin: 30 mg subcutaneous twice daily starting 12 hours before or after surgery, continued 10-14 days (consider up to 35 days) 1
- Rivaroxaban: 10 mg orally once daily starting 6-10 hours after surgery, continued 10-14 days (consider up to 35 days) 1
- Fondaparinux: 2.5 mg subcutaneous once daily beginning 6-8 hours postoperatively, continued 10-14 days (consider up to 35 days) 1
Extended prophylaxis (up to 35 days total) is strongly recommended for major orthopedic surgery given the persistent VTE risk 6, 9.
Nonorthopedic Surgery
Risk stratify using the Caprini score (very low 0 points, low 1-2 points, moderate 3-4 points, high >5 points) 1:
- Moderate-to-high risk without bleeding risk: LMWH or low-dose UFH combined with mechanical prophylaxis 1
- High bleeding risk: Mechanical prophylaxis alone until bleeding risk decreases, then add pharmacologic prophylaxis 1
- Duration: Minimum 7-10 days; consider extended prophylaxis up to 4 weeks for high-risk patients 3, 4
Surgical Dosing:
- UFH: 5000 U 2-4 hours preoperatively and every 8 hours thereafter 3, 4
- Enoxaparin: 40 mg once daily (can start 2-4 hours preoperatively or 10-12 hours preoperatively) 3, 1, 4
- Dalteparin: Low risk 2500 IU once daily; high risk 2500 IU 12 hours after surgery then 5000 IU once daily 1
Cancer Patients
Hospitalized cancer patients with acute illness should receive pharmacologic thromboprophylaxis in the absence of bleeding or contraindications. 3, 4
- UFH: 5000 U every 8 hours (more effective than every 12 hours in cancer patients) 3, 4
- LMWH or fondaparinux: Same dosing as general medical patients 3, 4
- Outpatient cancer patients: Selected high-risk patients on systemic chemotherapy may benefit from prophylaxis with LMWH, apixaban 2.5 mg twice daily, or rivaroxaban 10 mg once daily 4
Renal Dose Adjustments
Critical adjustments for renal impairment:
- Fondaparinux: CrCl 30-50 mL/min: reduce to 1.5 mg once daily; CrCl <30 mL/min: contraindicated 1
- Enoxaparin: CrCl <30 mL/min: reduce prophylactic dose to 30 mg once daily 5
- LMWH generally: Avoid or adjust dose based on anti-Factor Xa levels when CrCl <30 mL/min 3, 4
- UFH: No dose adjustment needed (not renally cleared) 3, 4
For patients weighing >150 kg, consider increasing enoxaparin prophylaxis to 40 mg every 12 hours 5.
Pregnant Patients
For pregnant women with acute VTE, use LMWH over unfractionated heparin (strong recommendation) 10.
Pregnancy-Specific Dosing:
- Treatment dose LMWH: Either once-daily or twice-daily dosing acceptable 10
- Dalteparin: 100 IU/kg every 12 hours or 200 IU/kg once daily 10
- Enoxaparin: 1 mg/kg every 12 hours or 1.5 mg/kg once daily 10
Do not routinely monitor anti-Factor Xa levels to guide LMWH dosing in pregnancy unless there are specific concerns 10.
For breastfeeding women requiring anticoagulation: UFH, LMWH, warfarin, acenocoumarol, fondaparinux, and danaparoid are all safe options (strong recommendation) 10.
Delivery Planning:
- Therapeutic-dose LMWH: Suggest scheduled delivery with prior discontinuation of anticoagulation 10
- Prophylactic-dose LMWH: Suggest against scheduled delivery with discontinuation 10
Common Pitfalls to Avoid
Do not use rivaroxaban for VTE prevention in acutely ill general medical patients - the MAGELLAN trial showed increased bleeding without clear benefit 1
Do not routinely use VTE prophylaxis in long-term care patients unless they have acute illness requiring hospitalization 2
Avoid combining dabigatran with antiplatelet agents (aspirin, clopidogrel) due to significantly increased bleeding risk 7
Do not place prophylactic IVC filters for primary prevention in orthopedic surgery patients 6
Neuraxial anesthesia timing: When epidural/spinal anesthesia is planned, prophylactic LMWH should not be given within 10-12 hours before the procedure. After catheter removal, wait at least 2 hours before administering LMWH 3
Starting too early after orthopedic surgery (<6 hours) increases bleeding without benefit 8